Table 4.
Pathways for the “interactions with leukocytes”
| Signaling pathways | HPG (d3) | PYS (d3) | PYS (d7) |
|---|---|---|---|
| IL-22 signaling | IL22RA2 | ||
| Th1 and Th2 Pathways or T helper cell differentiation | TNFSF4 | NOTCH2, NFIL3, IL4R, PSENEN, HLA-DMA, HLA-A, IL1RL1, FGFR1, MAF, HLA-DMB, CD274, MAK, BCL6 | HLA-DMB |
| LPS/IL-1 mediated inhibition of RXR function | CHST1 | IL1RL1, ABCC2, CPT2, HS3ST1, GSTO2, MGST3, ABCA1 | CHST1, SREBF1, MGST3 |
| IL-4, Nur77 signaling in T lymphocytes, or antigen presentation | HLA-DMA, HLA-A, HLA-DMB, IL4R, FGFR1 | HLA-DMB, TAPBP | |
| Leukocyte extravasation signaling | BTK, CLDN10, CLDN4, FGFR1, CD44, MMP12, BCAR1, CTNND1, PRKCA | MMP12 | |
| IL-6, IL-10, IL-17A, CD40 or TNFR1/2 signaling | COL1A1, CSNK2A2, FOS, TRAF5, FGFR1, IL4R, IL1RL1, ARG2, NAIP, | MAP3K14 | |
| IL-1 or IL-8 signaling | GNB4, FOS, GNAQ, RND3, FLT1, FGFR1, HBEGF, PRKCA | MAP3K14, GNAS | |
| GM-CSF, IL-2, IL-3, IL-7, IGF-1 or TGF-beta signaling | RUNX1, CSNK2A2, FOS, FGFR1, PRKCA, CDKN1B, YWHAE, BCL6, BMP4, SERPINE1 | ||
| IL-12 signaling or production in macrophages | FOS, ALB, ORM1, FGFR1, MAF, PRKCA | ||
| Natural killer cell signaling | FGFR1, SH3BP2, KIR3DL3, PRKCA | ||
| Cytotoxic T lymphocyte-mediated apoptosis of target cells, or granzyme B signaling | HLA-A, DFFB | ||
| Antiproliferative role of TOB in T cell signaling | TOB1, CDKN1B |
Three separate RNA samples were included in each group (n = 3). The upregulated transcripts were highlighted in bold. Others were downregulated